Navigation Links
Cardium Announces Follow-On Direct Investment by Institutional Investor
Date:6/30/2008

fications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.

Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium Therapeutics, Inc.

Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM) are trademarks of the Tissue Repair Company.

InnerCool Therapies(R), InnerCool(R), Celsius Control System(TM), Accutrol(TM), CoolBlue(TM) and RapidBlue(TM) are trademarks of InnerCool Therapies, Inc.


'/>"/>
SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cardium Selected for Inclusion in Russell Microcap Index
2. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
3. Cardium Launches New AWARE Clinical Study Website
4. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
5. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
6. Cardium Reports on First Quarter 2008 Highlights and Financial Results
7. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
8. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
9. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
10. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
11. Cardium Completes $5.3 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan ... Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at ... Delhi, India, November 22, 2009. Beike is China,s ... The conference, organized by ...
(Date:12/2/2009)... Dec. 2 Reportlinker.com announces that a ... its catalogue: ,, Carbondioxide Incubators - ... http://www.reportlinker.com/p0164368/Carbondioxide-Incubators---A-Global-Market-Perspective.html ,, Incubators are the ... cancer, research, and other applications for providing ...
(Date:12/2/2009)... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion ... trial of Cotara® in patients with relapsed glioblastoma multiforme ... is a targeted monoclonal antibody linked to a radioisotope ... Cotara specifically targets cells at the center of ...
(Date:12/2/2009)... Mass., Dec. 2 TechConnect World, an event ... product integration in cleantech, nanotech, biotech and MEMS, ... and business presentations. ,, Now in its 14th ... Science and Technology Institute (NSTI), and the Clean ...
Breaking Biology Technology:Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3
... and assemble MOD® units, an innovative medication dispenser produced by Avancen ... ... 2009 -- Zeus, Inc., a global leader in the design and ... with Avancen MOD Corporation. Avancen produces the MOD (Medication on ...
... 13 On February 10, 2009, NeoStem, Inc. (NYSE ... NYSE Alternext US (the "Alternext") indicating that the Company ... Alternext Company Guide (the "Guide"), which requires a listed ... November 3, 2008, the Company had announced that it ...
... facility opening in Second Quarter,TORONTO, Feb. 13 /PRNewswire-FirstCall/ ... despite a challenging year for the biopharmaceutical industry, ... advance toward the ultimate goal of sustained profitability. ... quarter ended December 31, 2008. , In a ...
Other Biology Technology:Zeus Partners with Avancen MOD Corp. 2NeoStem Receives Notice of Noncompliance from NYSE Alternext US 2Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 2Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 3Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 4
(Date:12/4/2009)... model of heart cells, University of Iowa investigators have ... II (CaM kinase), disrupts the electrical activity of heart ... Columbia University, was published online Dec. 3 in the ... researchers have developed great interest in calmodulin kinase II ...
(Date:12/3/2009)... plant and animal species can be likened to emptying a ... potential medicines into the trash, or replacing every local cuisine ... their habitats may not just make the world boring. New ... risk for catching some nasty disease. , "Habitat destruction and ...
(Date:12/3/2009)... Rapids, Mich. (Dec. 3, 2009) Van Andel ... hormone abscisic acid (ABA) works at the molecular level to ... cold. Their findings, published in the journal Nature ... around the world and combat global food shortages. The ...
Breaking Biology News(10 mins):U-Iowa study helps advance heart-related research 2Species down, disease up 2Species down, disease up 3Species down, disease up 4VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3More Swine Flu Vaccine Coming Soon 60183 1More Swine Flu Vaccine Coming Soon 60183 2More Swine Flu Vaccine Coming Soon 60183 3Section 1803 3A Senate Health Care Bill Makes Planned Parenthood Quasi Government Agency 3F Asks ALL 60180 1Section 1803 3A Senate Health Care Bill Makes Planned Parenthood Quasi Government Agency 3F Asks ALL 60180 21 800 Therapist Announces New Executive Team and Tele Therapy Offering 60177 11 800 Therapist Announces New Executive Team and Tele Therapy Offering 60177 2
... Rochelle, NY, July 8, 2008Biotech and pharmaceutical firms ... to streamline the complicated drug discovery process, reports ... GEN ). Most successful approaches rely on a ... advanced data-analysis tools, according to an article in ...
... at the Biodesign Institute at Arizona State University have made ... biologically engineered organism that can effectively deliver an antigen in ... to use live salmonella bacterium as the containment/delivery method for ... forward in development of a new means of biological containment ...
... suitable carrier for an oral vaccine against Alzheimer,s disease, ... of Bioscience and Biotechnology (KRIBB) in Korea and colleagues ... Science at Wonkwang University. Although their research (1), just ... is still in the early stages, it is a ...
Other Biology News:From foe to friend: Researchers use salmonella as a way to administer vaccines in the body 2From foe to friend: Researchers use salmonella as a way to administer vaccines in the body 3From foe to friend: Researchers use salmonella as a way to administer vaccines in the body 4Can tomatoes carry the cure for Alzheimer's? 2
... Glycine Transporter 2, Neuronal (GLYT2). The antiserum ... the central nervous system. The staining pattern ... described using in situ hybridization with probes ... been described for glycinergic neurons. Preabsorption of ...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
... OA-Hy cis- 9-Octadecenoyl-N-hydroxylamide ... LIGHT. PACKAGED UNDER INERT GAS. A potent ... dose-dependent manner (K i = 1.7 ... Soluble in EtOH or DMSO. Unstable in ...
... Reacts with an early protein. ... 3 hours post-infection exhibiting an ... peak intensity between 6-24 hours. ... intense coarsely granular staining. ...
Biology Products: